News - Pricing, Respiratory and Pulmonary

Filter

Popular Filters

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

19-02-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

GermanyNorthern EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryUltibro BreezhalerXoterna Breezhaler

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand

11-12-2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Pricing and reimbursement conditions for InterMune's Esbriet in Italy

17-06-2013

US biotech firm InterMune (Nasdaq: ITMN) says that the board of the Italian Drug Agency (AIFA) has approved…

BiotechnologyEsbrietEuropeInterMunePricingRespiratory and Pulmonary

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10-01-2013

The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis

30-11-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Proposal in relation to Actelion's Tracleer in New Zealand

01-10-2012

New Zealand's national pharmaceuticals funding agency PHARMAC is seeking feedback on a proposal in relation…

ActelionAsia-PacificBiotechnologyPricingRegulationRespiratory and PulmonaryTracleer

French price regulator authorizes reimbursement of InterMune's Esbriet

12-09-2012

USA-based InterMune (Nasdaq: ITMN) says that French regulator the Comite Economique des Produits de…

EsbrietEuropeInterMunePharmaceuticalPricingRespiratory and Pulmonary

New Zealand's PHARMAC to fund alternative treatments for asthma, scabies from Merck

31-07-2012

New Zealand's Pharmaceutical Management Agency PHARMAC is to fund a treatment for pre-schoolers with…

Asia-PacificDermatologicalsHealthcareMerck & CoPharmaceuticalPricingRespiratory and PulmonarySingulairStromectil

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

French Transparency Commission issues favorable opinion on Esbriet

10-04-2012

There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Esbriet offers additional benefit, says German G-BA

16-03-2012

USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

UK NICE says yes to Lilly’s Bydureon and ALK-Abello’s Pharmalgen

22-02-2012

The UK’s health care guidance body the National Institute for Health and Clinical Excellence (NICE),…

ALK AbelloBydureonDiabetesEli LillyEuropePharmaceuticalPharmalgenPricingRegulationRespiratory and Pulmonary

NICE publishes final technology appraisal guidance for four conditions

24-01-2012

The UK’s drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has today…

AvastinCardio-vascularDaxasEliquisErbituxEuropeOncologyPharmaceuticalPricingRegulationRespiratory and PulmonaryRituxanVectibix

NICE wants more data on Daxas

08-12-2011

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final…

DaxasEuropeMerck & CoPharmaceuticalPricingRegulationRespiratory and Pulmonary

UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen

30-09-2011

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning issued…

Alk-AbelloBenlystaEuropeGlaxoSmithKlineJevtanaOncologyPharmaceuticalPharmalgenPricingRare diseasesRegulationRespiratory and PulmonarySanofi

Draft guidance from UK's NICE recommends clinical trial for COPD drug Daxas

09-09-2011

New draft guidance from the UK's drug watchdog the National Institute for Health and Clinical Excellence…

DaxasEuropeMerck & CoNycomedPharmaceuticalPricingRegulationRespiratory and Pulmonary

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top